Poster Abstracts • OFID 2018:5 (Suppl 1) • S487 received TCD HCT and 11 (18%) received cord blood allograft. 67% of children and 82% of adults had maximum ADV VL >1,000 copies/mL. The median maximum VL was 2.8 log 10 copies/mL in Q1, 4.4 log 10 copies/mL in Q2, 5.0 log 10 copies/mL in Q3, 5.3 log 10 copies/mL in Q4, respectively. Figure shows survival estimate by AAUC Q. Higher AAUC was associated with lower survival. After adjusting for covariates, AAUC (hazard ratio [HR] 1.9; 95% confidence interval [CI] 1.2-3.0, P = 0.0065) were associated with mortality. Among other covariates, only aGVHD was associated with mortality (HR 11.7;, P = 0.049).
Background. Antiviral prophylaxis to prevent PTLD remains controversial, but some data suggest that valganciclovir or ganciclovir ([val] ganciclovir) use in EBV highrisk pediatric renal transplants reduces EBV viremia. We evaluated the impact of [val] ganciclovir on EBV viremia and post-transplant lymphoproliferative disease (PTLD) in pediatric nonrenal SOT recipients.
Methods. Retrospective study of 100 patients who underwent a first heart, liver, lung, intestine, or multivisceral SOT between November 2013 and November 2016 at Boston Children's Hospital who survived without re-transplantation for at least 30 days. Data collected included EBV donor/recipient serostatus, donor's age >2 years-old (to avoid misclassification of EBV risk due to maternal antibody), antiviral use ([val] ganciclovir or acyclovir), time to EBV viremia (>1,000 copies/mL by whole blood PCR), and time to development of PTLD. EBV high-risk patients were those with donor EBV positive [D+]/recipient EBV negative [R-] serologies; intermediate-risk were EBV R+; low risk were EBV D-/R-. Time-to-event analysis using the Kaplan-Meier method was performed and significance (P = 0.05) was evaluated using the log-rank test.
Results. High (n = 45) or intermediate (n = 27) EBV risk was associated with increased EBV viremia (P = 0.007, table). EBV viremia was significantly decreased in the subgroup of high-risk patients with donors >2 years old who received [val] ganciclovir vs. those who received no antiviral (n = 23, n = 4, P = 0.03, Figure 1 ). Most PTLD cases (8/9) occurred in the high-risk group (P = 0.03, Figure 2 ). Overall, patients who received [val] ganciclovir had less PTLD than those who did not (P = 0.03), but this was not significant in the high-risk subgroup (P = 0.14, Figure 3 ). Background. Cellular immunity plays a critical role in controlling cytomegalovirus (CMV) infection after solid-organ transplantation (SOT). We correlated lymphocyte subsets with the risk and course of CMV after SOT.
Conclusion. Lower rates of EBV viremia occurred in high EBV
Methods. We studied 130 selected kidney, heart, lung, pancreas, liver and composite tissue transplant patients who had blood samples collected for immunologic testing. We abstracted absolute lymphocyte count (ALC) and CD4+ and CD8+ T cell subsets, and correlated them with CMV infection and disease. CMV infection was diagnosed by quantitative PCR in blood and other clinical samples, or histopathology.
Results. Fifty-nine of 130 SOT patients developed CMV infection or disease. The median age was 57.5 years (IQR: 47.8-64). Gender distribution was equal. The median onset to CMV infection or disease was 10.5 months (IQR 5.5-18.7). The median ALC for the whole cohort was 565 (IQR, 310-1,083) cells/mm 3 . An ALC <630 cells/mm 3 was correlated with CMV infection or disease (sensitivity 83%; specificity 70%). The median CD4+ T cell count for the whole cohort was 160.5 (IQR, 17.5-424.5) cells/mm 3 . Patients with CD4+ T cell count <196 cells/mm 3 were at a higher risk of CMV infection or disease (sensitivity 88%; specificity 71%). The 59 SOT recipients with CMV infection or disease had a significantly lower median number of CD4+ T cells compared with those who did not develop CMV (29 vs. 325.5 cells/mm 3 , P < 0.0001). A median CD4+ T cell count <45 cells/mm 3 was associated with CMV syndrome or tissue-invasive disease (sensitivity 66%; specificity 68%). Patients who had CMV relapse had significantly lower median CD4+ T cell count (9 vs. 68 cells/mm 3 , P = 0.005). There was no association between CD8+ T cell count and CMV infection or disease. However, T cell functional analysis was not considered in this analysis.
Conclusion. Lower ALC and CD4+ counts, but not CD8+ T cell count, are significantly correlated with the risk and course of CMV infection and disease after SOT. These readily available clinical measures have the potential to assist in CMV disease management. Friday, October 5, 2018: 12:30 PM Background. Cytomegalovirus (CMV) infection causes significant morbidity after transplant. Patients can be stratified by donor and recipient CMV serostatus, but the infection phenotype remains variable. We hypothesized that some of this variability might be explained by circadian rhythms influenced by time of transplant.
Is Primary CMV Infection Post-transplant Influenced by Circadian
Methods. Virological, demographic and transplant data were reviewed for liver and kidney transplant patients (n = 1,111) managed between 2002 and 2015 using pre-emptive therapy. Donor circulatory arrest time and reperfusion time in the recipient were split into four categories, chosen a priori. Patients were categorised into three groups depending on donor and recipient CMV serostatus. Differences between groups were assessed using chi-squared and Kruskall-Wallis tests.
Results. For the donor seropositive/recipient seronegative group (D+R−) all CMV parameters were highest when reperfusion occurred in the day or evening, and the lowest in the night or morning (see table) . 
